Bacterium-like particles derived from the respiratory commensal bacteria corynebacterium pseudodiphtheriticum 090104 as a promising mucosal adjuvant

Autores
Ortiz Moyano, Ramiro; Raya Tonetti, María Fernanda; Sacur, Jacinto Alfredo; Tomokiyo, Mikado; Melnikov, Vyacheslav; Alvarez, Susana; Kitazawa, Haruki; Vizoso Pinto, María Guadalupe; Villena, Julio Cesar
Año de publicación
2021
Idioma
inglés
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
Corynebacterium pseudodiphtheriticum is a Gram-positive bacterium that is part of the nasopharyngeal microbiota. Cp was shown to prevent the colonization of the respiratory mucosa by pathogenic bacteria including Streptococcus pneumoniae (Sp). We recently demonstrated that C. pseudodiphtheriticum 090104 (Cp), when nasally administered to mice; differentially modulated the respiratory immune responses triggered by TLR2 and improved the resistance to pneumococcal pneumonia. We also reported that bacterium-like particles derived from Cp (BPCp) had the ability to modulate the innate respiratory immunity. These results allowed us to hypothesize that Cp or BPCp could be used as mucosal adjuvants to enhance the respiratory adaptive immunity. In this work, infant Swiss-albino mice were nasally immunized with 6.25 pg of Pneumovax23® vaccine (PV), PV plus Cp (108 CFU) or PV plus BPCp at days 0, 14 and 28. Seven days after the last immunization samples of bronco-alveolar lavages (BAL) and serum were collected for specific antibodies determinations. In addition, immunized mice were challenged with Sp serotypes 6B or 19F (106 CFU) and the resistance to the infection was evaluated 2 days after the challenge. Mice in the PV+Cp and PV+BPCp groups had significantly higher levels of BAL anti-Sp IgG and IgA (p<0.01) as well as serum IgG and IgM (p<0.01) in comparison with mice immunized only with PV. Of note, the PV+Cp immunization was more efficient than PV+BPCp to improve respiratory and serum antibodies levels. PV+Cp and PV+BPCp mice had lower Sp counts in lungs than controls, as well as negative hemocultures. In addition, PV+Cp and PV+BPCp groups had higher levels of BAL and serum TNF-α, IFN-γ and IL-4 (p<0.05) than controls after Sp infection. Again, Cp was more efficient than BPCp to induce protection against Sp 6B and 19F. The results show that both Cp and BPCp are promising mucosal adjuvants for the development of nasal vaccines to combat respiratory infections.
Fil: Ortiz Moyano, Ramiro. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
Fil: Raya Tonetti, María Fernanda. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
Fil: Sacur, Jacinto Alfredo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Instituto Superior de Investigaciones Biológicas. Universidad Nacional de Tucumán. Instituto Superior de Investigaciones Biológicas; Argentina
Fil: Tomokiyo, Mikado. Tohoku University; Japón
Fil: Melnikov, Vyacheslav. Gabrichevsky Research Institute of Epidemiology and Microbiology; Rusia
Fil: Alvarez, Susana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
Fil: Kitazawa, Haruki. Tohoku University; Japón
Fil: Vizoso Pinto, María Guadalupe. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Instituto Superior de Investigaciones Biológicas. Universidad Nacional de Tucumán. Instituto Superior de Investigaciones Biológicas; Argentina
Fil: Villena, Julio Cesar. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunión Anual de la Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de Nanomedicinas
Argentina
Sociedad Argentina de Inmunologia
Sociedad Argentina de Investigación Clínica
Asociación Argentina de Farmacología Experimental
Asociación Argentina de Nanomedicinas
Materia
Corynebacterium pseudodiphtheriticum
PNEUMONIA
RESPIRATORY IMMUNE RESPONSE
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/260666
Acceder
id CONICETDig_a8adc1698e298aecdb3382f590f5c774
oai_identifier_str oai:ri.conicet.gov.ar:11336/260666
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Bacterium-like particles derived from the respiratory commensal bacteria corynebacterium pseudodiphtheriticum 090104 as a promising mucosal adjuvantOrtiz Moyano, RamiroRaya Tonetti, María FernandaSacur, Jacinto AlfredoTomokiyo, MikadoMelnikov, VyacheslavAlvarez, SusanaKitazawa, HarukiVizoso Pinto, María GuadalupeVillena, Julio CesarCorynebacterium pseudodiphtheriticumPNEUMONIARESPIRATORY IMMUNE RESPONSEhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Corynebacterium pseudodiphtheriticum is a Gram-positive bacterium that is part of the nasopharyngeal microbiota. Cp was shown to prevent the colonization of the respiratory mucosa by pathogenic bacteria including Streptococcus pneumoniae (Sp). We recently demonstrated that C. pseudodiphtheriticum 090104 (Cp), when nasally administered to mice; differentially modulated the respiratory immune responses triggered by TLR2 and improved the resistance to pneumococcal pneumonia. We also reported that bacterium-like particles derived from Cp (BPCp) had the ability to modulate the innate respiratory immunity. These results allowed us to hypothesize that Cp or BPCp could be used as mucosal adjuvants to enhance the respiratory adaptive immunity. In this work, infant Swiss-albino mice were nasally immunized with 6.25 pg of Pneumovax23® vaccine (PV), PV plus Cp (108 CFU) or PV plus BPCp at days 0, 14 and 28. Seven days after the last immunization samples of bronco-alveolar lavages (BAL) and serum were collected for specific antibodies determinations. In addition, immunized mice were challenged with Sp serotypes 6B or 19F (106 CFU) and the resistance to the infection was evaluated 2 days after the challenge. Mice in the PV+Cp and PV+BPCp groups had significantly higher levels of BAL anti-Sp IgG and IgA (p<0.01) as well as serum IgG and IgM (p<0.01) in comparison with mice immunized only with PV. Of note, the PV+Cp immunization was more efficient than PV+BPCp to improve respiratory and serum antibodies levels. PV+Cp and PV+BPCp mice had lower Sp counts in lungs than controls, as well as negative hemocultures. In addition, PV+Cp and PV+BPCp groups had higher levels of BAL and serum TNF-α, IFN-γ and IL-4 (p<0.05) than controls after Sp infection. Again, Cp was more efficient than BPCp to induce protection against Sp 6B and 19F. The results show that both Cp and BPCp are promising mucosal adjuvants for the development of nasal vaccines to combat respiratory infections.Fil: Ortiz Moyano, Ramiro. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: Raya Tonetti, María Fernanda. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: Sacur, Jacinto Alfredo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Instituto Superior de Investigaciones Biológicas. Universidad Nacional de Tucumán. Instituto Superior de Investigaciones Biológicas; ArgentinaFil: Tomokiyo, Mikado. Tohoku University; JapónFil: Melnikov, Vyacheslav. Gabrichevsky Research Institute of Epidemiology and Microbiology; RusiaFil: Alvarez, Susana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: Kitazawa, Haruki. Tohoku University; JapónFil: Vizoso Pinto, María Guadalupe. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Instituto Superior de Investigaciones Biológicas. Universidad Nacional de Tucumán. Instituto Superior de Investigaciones Biológicas; ArgentinaFil: Villena, Julio Cesar. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaLXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunión Anual de la Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de NanomedicinasArgentinaSociedad Argentina de InmunologiaSociedad Argentina de Investigación ClínicaAsociación Argentina de Farmacología ExperimentalAsociación Argentina de NanomedicinasFundación Revista Medicina2021info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectReuniónJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/vnd.openxmlformats-officedocument.wordprocessingml.documentapplication/pdfhttp://hdl.handle.net/11336/260666Bacterium-like particles derived from the respiratory commensal bacteria corynebacterium pseudodiphtheriticum 090104 as a promising mucosal adjuvant; LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunión Anual de la Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de Nanomedicinas; Argentina; 2021; 122-1221669-9106CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.reunionbiociencias.com.ar/wp-content/uploads/2021/11/Revista-Medicina-2021.pdfInternacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:47:34Zoai:ri.conicet.gov.ar:11336/260666instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:47:35.081CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Bacterium-like particles derived from the respiratory commensal bacteria corynebacterium pseudodiphtheriticum 090104 as a promising mucosal adjuvant
title Bacterium-like particles derived from the respiratory commensal bacteria corynebacterium pseudodiphtheriticum 090104 as a promising mucosal adjuvant
spellingShingle Bacterium-like particles derived from the respiratory commensal bacteria corynebacterium pseudodiphtheriticum 090104 as a promising mucosal adjuvant
Ortiz Moyano, Ramiro
Corynebacterium pseudodiphtheriticum
PNEUMONIA
RESPIRATORY IMMUNE RESPONSE
title_short Bacterium-like particles derived from the respiratory commensal bacteria corynebacterium pseudodiphtheriticum 090104 as a promising mucosal adjuvant
title_full Bacterium-like particles derived from the respiratory commensal bacteria corynebacterium pseudodiphtheriticum 090104 as a promising mucosal adjuvant
title_fullStr Bacterium-like particles derived from the respiratory commensal bacteria corynebacterium pseudodiphtheriticum 090104 as a promising mucosal adjuvant
title_full_unstemmed Bacterium-like particles derived from the respiratory commensal bacteria corynebacterium pseudodiphtheriticum 090104 as a promising mucosal adjuvant
title_sort Bacterium-like particles derived from the respiratory commensal bacteria corynebacterium pseudodiphtheriticum 090104 as a promising mucosal adjuvant
dc.creator.none.fl_str_mv Ortiz Moyano, Ramiro
Raya Tonetti, María Fernanda
Sacur, Jacinto Alfredo
Tomokiyo, Mikado
Melnikov, Vyacheslav
Alvarez, Susana
Kitazawa, Haruki
Vizoso Pinto, María Guadalupe
Villena, Julio Cesar
author Ortiz Moyano, Ramiro
author_facet Ortiz Moyano, Ramiro
Raya Tonetti, María Fernanda
Sacur, Jacinto Alfredo
Tomokiyo, Mikado
Melnikov, Vyacheslav
Alvarez, Susana
Kitazawa, Haruki
Vizoso Pinto, María Guadalupe
Villena, Julio Cesar
author_role author
author2 Raya Tonetti, María Fernanda
Sacur, Jacinto Alfredo
Tomokiyo, Mikado
Melnikov, Vyacheslav
Alvarez, Susana
Kitazawa, Haruki
Vizoso Pinto, María Guadalupe
Villena, Julio Cesar
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Corynebacterium pseudodiphtheriticum
PNEUMONIA
RESPIRATORY IMMUNE RESPONSE
topic Corynebacterium pseudodiphtheriticum
PNEUMONIA
RESPIRATORY IMMUNE RESPONSE
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Corynebacterium pseudodiphtheriticum is a Gram-positive bacterium that is part of the nasopharyngeal microbiota. Cp was shown to prevent the colonization of the respiratory mucosa by pathogenic bacteria including Streptococcus pneumoniae (Sp). We recently demonstrated that C. pseudodiphtheriticum 090104 (Cp), when nasally administered to mice; differentially modulated the respiratory immune responses triggered by TLR2 and improved the resistance to pneumococcal pneumonia. We also reported that bacterium-like particles derived from Cp (BPCp) had the ability to modulate the innate respiratory immunity. These results allowed us to hypothesize that Cp or BPCp could be used as mucosal adjuvants to enhance the respiratory adaptive immunity. In this work, infant Swiss-albino mice were nasally immunized with 6.25 pg of Pneumovax23® vaccine (PV), PV plus Cp (108 CFU) or PV plus BPCp at days 0, 14 and 28. Seven days after the last immunization samples of bronco-alveolar lavages (BAL) and serum were collected for specific antibodies determinations. In addition, immunized mice were challenged with Sp serotypes 6B or 19F (106 CFU) and the resistance to the infection was evaluated 2 days after the challenge. Mice in the PV+Cp and PV+BPCp groups had significantly higher levels of BAL anti-Sp IgG and IgA (p<0.01) as well as serum IgG and IgM (p<0.01) in comparison with mice immunized only with PV. Of note, the PV+Cp immunization was more efficient than PV+BPCp to improve respiratory and serum antibodies levels. PV+Cp and PV+BPCp mice had lower Sp counts in lungs than controls, as well as negative hemocultures. In addition, PV+Cp and PV+BPCp groups had higher levels of BAL and serum TNF-α, IFN-γ and IL-4 (p<0.05) than controls after Sp infection. Again, Cp was more efficient than BPCp to induce protection against Sp 6B and 19F. The results show that both Cp and BPCp are promising mucosal adjuvants for the development of nasal vaccines to combat respiratory infections.
Fil: Ortiz Moyano, Ramiro. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
Fil: Raya Tonetti, María Fernanda. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
Fil: Sacur, Jacinto Alfredo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Instituto Superior de Investigaciones Biológicas. Universidad Nacional de Tucumán. Instituto Superior de Investigaciones Biológicas; Argentina
Fil: Tomokiyo, Mikado. Tohoku University; Japón
Fil: Melnikov, Vyacheslav. Gabrichevsky Research Institute of Epidemiology and Microbiology; Rusia
Fil: Alvarez, Susana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
Fil: Kitazawa, Haruki. Tohoku University; Japón
Fil: Vizoso Pinto, María Guadalupe. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Instituto Superior de Investigaciones Biológicas. Universidad Nacional de Tucumán. Instituto Superior de Investigaciones Biológicas; Argentina
Fil: Villena, Julio Cesar. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunión Anual de la Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de Nanomedicinas
Argentina
Sociedad Argentina de Inmunologia
Sociedad Argentina de Investigación Clínica
Asociación Argentina de Farmacología Experimental
Asociación Argentina de Nanomedicinas
description Corynebacterium pseudodiphtheriticum is a Gram-positive bacterium that is part of the nasopharyngeal microbiota. Cp was shown to prevent the colonization of the respiratory mucosa by pathogenic bacteria including Streptococcus pneumoniae (Sp). We recently demonstrated that C. pseudodiphtheriticum 090104 (Cp), when nasally administered to mice; differentially modulated the respiratory immune responses triggered by TLR2 and improved the resistance to pneumococcal pneumonia. We also reported that bacterium-like particles derived from Cp (BPCp) had the ability to modulate the innate respiratory immunity. These results allowed us to hypothesize that Cp or BPCp could be used as mucosal adjuvants to enhance the respiratory adaptive immunity. In this work, infant Swiss-albino mice were nasally immunized with 6.25 pg of Pneumovax23® vaccine (PV), PV plus Cp (108 CFU) or PV plus BPCp at days 0, 14 and 28. Seven days after the last immunization samples of bronco-alveolar lavages (BAL) and serum were collected for specific antibodies determinations. In addition, immunized mice were challenged with Sp serotypes 6B or 19F (106 CFU) and the resistance to the infection was evaluated 2 days after the challenge. Mice in the PV+Cp and PV+BPCp groups had significantly higher levels of BAL anti-Sp IgG and IgA (p<0.01) as well as serum IgG and IgM (p<0.01) in comparison with mice immunized only with PV. Of note, the PV+Cp immunization was more efficient than PV+BPCp to improve respiratory and serum antibodies levels. PV+Cp and PV+BPCp mice had lower Sp counts in lungs than controls, as well as negative hemocultures. In addition, PV+Cp and PV+BPCp groups had higher levels of BAL and serum TNF-α, IFN-γ and IL-4 (p<0.05) than controls after Sp infection. Again, Cp was more efficient than BPCp to induce protection against Sp 6B and 19F. The results show that both Cp and BPCp are promising mucosal adjuvants for the development of nasal vaccines to combat respiratory infections.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/conferenceObject
Reunión
Journal
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
status_str publishedVersion
format conferenceObject
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/260666
Bacterium-like particles derived from the respiratory commensal bacteria corynebacterium pseudodiphtheriticum 090104 as a promising mucosal adjuvant; LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunión Anual de la Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de Nanomedicinas; Argentina; 2021; 122-122
1669-9106
CONICET Digital
CONICET
url http://hdl.handle.net/11336/260666
identifier_str_mv Bacterium-like particles derived from the respiratory commensal bacteria corynebacterium pseudodiphtheriticum 090104 as a promising mucosal adjuvant; LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunión Anual de la Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de Nanomedicinas; Argentina; 2021; 122-122
1669-9106
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.reunionbiociencias.com.ar/wp-content/uploads/2021/11/Revista-Medicina-2021.pdf
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/vnd.openxmlformats-officedocument.wordprocessingml.document
application/pdf
dc.coverage.none.fl_str_mv Internacional
dc.publisher.none.fl_str_mv Fundación Revista Medicina
publisher.none.fl_str_mv Fundación Revista Medicina
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846782180991172608
score 12.982451

Publicaciones similares